Identification and Characterization of Inhibitors of Multidrug Resistance Efflux Pumps in Pseudomonas aeruginosa: Novel Agents for Combination Therapy

By O. Lomovskaya, M. S. Warren, Angela Lee, J. Galazzo, R. Fronko, M. Lee, Johanne Blais, D. Cho, S. Chamberland, T. Renau and 6 more. Antimicrobial Agents and Chemotherapy, 2001

891 citations recorded by the source corpus.

Subfields: Molecular Biology, Molecular Medicine, Pharmacology

View Paper: https://www.semanticscholar.org/paper/6694a0ddd3a47d05d07da56fa6912e7a205ad12b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Xian-Zhi Li
2. L. Piddock
3. P. Nordmann
4. H. Nikaido
5. L. Poirel

In Molecular Medicine

1. Xian-Zhi Li
2. H. Nikaido
3. L. Piddock
4. P. Nordmann
5. P. Plésiat
6. L. Poirel
7. J. Pagés
8. Gerard D. Wright

In Pharmacology

1. H. Nikaido
2. Xian-Zhi Li
3. P. Nordmann
4. Gerard D. Wright
5. T. Grossman

Citations in the corpus

• Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? (2002, positive): “For the long term, multidrug efflux inhibitors are promising for use with fluoroquinolones or b-lactams [28], and metallo–b-lactamase inhibitors [29] are the focus of laboratory investigation.”
• Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. (2007, background): “aeruginosa [187,188], with one compound now in phase I of clinical development for use as an aerosol with cystic fibrosis patients (http://www.”
• Adaptive and Mutational Resistance: Role of Porins and Efflux Pumps in Drug Resistance (2012, background): “Strains that overproduce the MexEF-OprN efflux pump are called nfxC-type strains, because of their resistance to norfloxacin.”
• The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria (2015, background): “Scientists at Microcide reported that the fermentation product of Streptomyces spp. contained two polycyclic compounds that showed strong potentiation of levofloxacin activity against the P. April 2015 Volume 28 Number 2 cmr.asm.org 385Clinical Microbiology Reviews aeruginosa MexAB-OprM system (revi”
• Clinically Relevant Chromosomally Encoded Multidrug Resistance Efflux Pumps in Bacteria (2006, background): “(106) also showed that the efflux pump inhibitor MC-207-110 suppressed the emergence of levofloxacin-resistant P.”